Renal Cell Carcinoma Diagnostics
Renal Cell Carcinoma Diagnostics
Advertisement
Chinmay Jani, MDRenal Cell Carcinoma Diagnostics | June 26, 2025
Drs. Joyce and Jani look toward the future of liquid biopsy in RCC care and how new technology, like AI, will play a role.
View More
Chinmay Jani, MDRenal Cell Carcinoma Diagnostics | June 26, 2025
Drs. Joyce and Jani discuss practical clinical cases of using liquid biopsy to manage patients in different RCC settings.
Chinmay Jani, MDRenal Cell Carcinoma Diagnostics | June 26, 2025
Drs. Joyce and Jani talk about the technique of liquid biopsy and its role as a diagnostic tool in RCC.
Marc Machaalani, MDRenal Cell Carcinoma Diagnostics | June 11, 2025
Dr. Machaalani highlights his study that evaluated the association between circulating KIM-1 and mRCC tumor biology.
Lauren Dembeck, PhDRenal Cell Carcinoma Diagnostics | May 30, 2025
High KIM-1 may be a biomarker of poor prognosis in RCC and correlates with specific LOF mutations, transcriptions programs.
Lauren Dembeck, PhDRenal Cell Carcinoma Diagnostics | May 30, 2025
68Ga-NY104 detected using PET/CT shows better diagnostic efficacy than 18F-FDG PET/CT in patients with mccRCC.
Reuben Ben-David, MDRenal Cell Carcinoma Diagnostics | April 30, 2025
Drs. Ben-David and Joyce evaluate the performance of ctDNA in detecting localized RCC disease recurrence after surgery.
Reuben Ben-David, MDRenal Cell Carcinoma Diagnostics | April 30, 2025
Drs. Ben-David, Joyce share an analysis on recurrence-free survival according to ctDNA status in patients with renal masses.
Brandon TwyfordRenal Cell Carcinoma Diagnostics | April 27, 2025
Pre-op ctDNA in localized RCC is linked to aggressive tumor features and worse RFS, highlighting its prognostic potential.
Daniel Joyce, MDRenal Cell Carcinoma Diagnostics | April 16, 2025
CA9 imaging and ZIRCON data offer new insight into managing small renal masses and supporting personalized kidney cancer care
Daniel Joyce, MDRenal Cell Carcinoma Diagnostics | April 16, 2025
Drs. Joyce and Chang discuss diagnostic strategies and future innovations in managing small renal masses.
Emily MenendezRenal Cell Carcinoma Diagnostics | March 4, 2025
A recent proof-of-concept study has further evaluated the efficacy of PSMA-guided MDT for oligometastatic RCC.
Daniel Joyce, MDRenal Cell Carcinoma Diagnostics | January 22, 2025
Dr. Dan Joyce discusses key SUO studies on RCC prognostics, personalized medicine, and advancements in treatment strategies.
Jose A. Karam, MD, FACSLocalized Renal Cell Carcinoma | January 21, 2025
Dr. Karam explains the main points of emphasis when it comes to small renal masses and surveillance versus surgery.
Emily MenendeznccRCC | January 16, 2025
Serial ctDNA negativity or clearance was linked to improved PFS compared with persistent ctDNA positivity during treatment.
Emily MenendezRenal Cell Carcinoma Diagnostics | January 3, 2025
The phase 3 ZIRCON trial demonstrated positive results with use of the agent for patients with ccRCC.
Brian Shuch, MDRenal Cell Carcinoma Diagnostics | January 9, 2025
Dr. Brian Shuch gives a preview of Urology on the Beach 2025, including his session on molecular imaging agents.
Brian Shuch, MDRenal Cell Carcinoma Diagnostics | December 19, 2024
Dr. Shuch shares the key points from his presentation on advancements in molecular imaging for RCC from SUO 2024.
Yvette C. TerrieRenal Cell Carcinoma Diagnostics | December 16, 2024
Higher PSMA expression in non-metastatic ccRCC correlates with improved progression-free survival, study shows.
Kaitlyn KoskoRenal Cell Carcinoma Diagnostics | December 5, 2024
For the study, researchers identified potential protein biomarkers for diagnosing and prognosticating renal cell carcinoma.
Advertisement
Advertisement